European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication
RTTNews·2026-03-13 14:16The European Commission delivered notable regulatory decisions this week - expanding the indication for Johnson & Johnson's prostate cancer therapy, approving a new dosing regimen for Protalix BioTherapeutics' enzyme replacement therapy Elfabrio, and granting a second indication to Incyte's immuno-oncology drug Zynyz.Johnson & Johnson (JNJ)On March 9, 2026, the European Commission approved Johnson & Johnson's AKEEGA with prednisone or prednisolone in combination with androgen deprivation therapy (ADT) for ...